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Background: Antipsychotic drugs can be used to help treat a wide variety of psychiatric disorders. However,
specific antipsychotic drugs for any particular patient may need to be changed for a number of different reasons,
including a lack of therapeutic efficacy and / or intolerance to medication side-effects. Drug switching may occur
through a limited number of established patterns. The nature of these changes is not well characterized in youth,
despite their frequent occurrence.
Methods: A retrospective analysis of antipsychotic drug switches was conducted on patients who had been
admitted as inpatients to a tertiary care child and adolescent psychiatric institute. PharmaNet (a large, central
administrative database) records of all medications prescribed in the 52 weeks prior to admission, and then
between admission and discharge, were analyzed for switching patterns. Additional data regarding diagnoses were
obtained from medical chart review.
Results: Patients represented a diagnostically heterogeneous population, and almost all antipsychotic drugs were
administered off-label. In the one year prior to and during admission to the hospital, a total of 31 out of 139
patients switched antipsychotic drugs. The frequency of switching increased closer to the time of admission, and
the proportional rate of switching was even higher during hospital stay. The most common switch was from
risperidone to quetiapine. Our analysis identified three main patterns of drug switching, all occurring with similar
frequency: titrated drug switches, abrupt drug switches and concurrent drug administration.
Conclusions: The present study indicates that antipsychotic drug switching in youth may be relatively common,
particularly in the year prior to hospitalization. No specific manner of drug switching predominates. This study also
demonstrates the feasibility of using large administrative databases to characterise switching patterns in youth.
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Due in large part to the advent of the second-generation
antipsychotic drugs that are associated with fewer neu-
rological side-effects than their predecessors, there has
been a widespread recent increase in the utilization of
antipsychotic drugs. This has included the expansion of
their use to include disorders other than psychosis, for
both on- and off-label indications [1]. One patient po-
pulation than has experienced a particularly rapid in-
crease in the rate of treatment with second-generation* Correspondence: al.barr@ubc.ca
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reproduction in any medium, provided the orantipsychotic drugs is youth. Rates of antipsychotic drug
use among children and adolescents are at historic highs
[2,3], and this includes a large proportion of patients
treated for off-label indications [4-6]. Studies of this
population have extensively described the patterns and
treatment strategies for antipsychotic drug use in youth:
topics range from clinical efficacy [7-9] through to drug
associated side-effects [10-12]. However, almost no re-
search has focused on the nature of switching from one
antipsychotic drug to another, which is a common and
important consideration in the treatment of children
and adolescents with second-generation antipsychotic
drugs.
Switching between antipsychotic drugs may occur for
a number of different reasons, in both the youth andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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causes, regardless of indication, relates to a lack of clin-
ical efficacy [13]. A failure of the patient to respond ad-
equately, and for the drug to show minimal impact on
psychiatric symptoms, represents a major rationale for
antipsychotic drug switching. Similarly, a lack of toler-
ance to second-generation antipsychotic drug-associated
side-effects, which typically include cardio-metabolic
sequelae [14-18], may result in a change of antipsy-
chotic medication [19]. Interestingly, a retrospective
study by Nyhius and colleagues [20] of antipsychotic
drug switching in the adult population found that the
two strongest predictors of switching early during
antipsychotic drug treatment related to a worsening
of akathisia and an increase in depression/anxiety
symptoms.
In adults, not only the drugs which are used during
the switch itself, but also the manner in which a switch
is managed, can strongly increase the risk of developing
additional adverse effects, that may include symptom
relapse [21,22]. Despite these risks, there are often bene-
fits conferred by selecting an alternative antipsychotic
medication [23]. Switching antipsychotic medications
happens frequently in adults, with two U.S. studies pro-
viding estimates of between 29.5% [20] and 42% [24] of
patients treated with antipsychotics switching drugs per
year. Although the risk of rebound or relapse effects has
been noted in poorly managed switches [25], we were
unable, in a thorough search of the literature, to identify
previous studies that had systematically described the
prevalence of different techniques of switching anti-
psychotic drugs (although see [26]). In addition, there is
also an absence of data describing the frequency and the
nature of antipsychotic drug switches in juveniles.
In the present study, we therefore evaluated the fre-
quency and patterns of antipsychotic drug switching in
youth in the year preceding their admission to a tertiary
care psychiatric institute. Our data consist of prescrip-
tions made to inpatients on the psychiatric wards of
a pediatric tertiary care facility in Vancouver, British
Columbia, as well as all prescriptions made to these pa-
tients during the 52-week period prior to their admis-
sion. At this tertiary care facility, patients treated with
antipsychotic drugs represented a wide range of different
psychiatric disorders, and as such are a heterogeneous
population. Off-label use of antipsychotics in youth is
common in this population, which includes disorders
other than psychosis. In large part , this is because anti-
psychotic drugs are used to treat symptoms that are
common across multiple diagnostic boundaries, such as
behavioral dysregulation [27]. We used a simple and
novel analysis to identify and characterize switches be-
tween antipsychotic medications. Due to the nature of
our data, it was also possible to examine when, relativeto the date of admission, switches were performed, and
the prevalence of different switching methods. Addition-
ally, we describe the choices of drugs that were used in
this cohort, both in the community and following admis-
sion to the hospital.
Methods
The present study represents a retrospective analysis of
data from all patients, aged 18 years and under, who
were admitted to the psychiatric inpatient program at
the tertiary care BC Children’s Hospital in Vancouver,
British Columbia, Canada. Patients were identified based
on admission to one of the psychiatric wards at the B.C.
Children’s Hospital between May 1, 2008 and December
31, 2009. The Child and Youth Mental Health Program
at B.C. Children’s Hospital is a Provincial resource pro-
viding mental health assessment and specialized treat-
ment for the entire Province. It is also the Province’s
main treatment, research and teaching facility for youth
mental health. The study protocol was approved by the
University of British Columbia Research Ethics Board.
The study was conducted in accordance with the princi-
ples of Good Clinical Practices and the Declaration of
Helsinki.
To investigate psychotropic medication use in the
52 weeks prior to hospital admission, data were obtained
for prescriptions during this period through B.C.
PharmaNet, which is a Province-wide network that links
all pharmacies in B.C. to a central set of data systems
[28] and can provide medication records as far back as
14 months. PharmaNet records contain information
including the prescribing physician, name and manu-
facturer of the drug, quantity dispensed, dose and
directions for the patient. To investigate medications
prescribed during hospitalization, which includes the en-
tire period between admission and discharge, data were
abstracted from the Department of Pharmacy’s computer
database (GE Centricity Pharmacy, v8.2). Data collected
from B.C. PharmaNet and the Department of Pharmacy
included the following list of medications: antipsycho-
tics, antidepressants, mood stabilizers, benzodiazepines,
anticholinergics, stimulants, and sleep medications. This
method did not include “as needed” hora somni medica-
tions. A total of 335 patients were identified based on
their admission date to the B.C. Children’s Hospital; 302
of these patients had complete information. These re-
cords were used to characterize modifications made to
antipsychotic therapy (including starting antipsychotic
therapy, discontinuation of antipsychotic therapy and
switching antipsychotic medications), and the drugs,
cross-tapering strategies, and doses involved in anti-
psychotic switches.
“Starts” were defined as a new prescription recorded
after at least 3 weeks with no previous antipsychotic
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discontinuation of an antipsychotic drug for at least
3 weeks, without a new prescription of another anti-
psychotic medication. “Switches” were defined as when
one antipsychotic was terminated and a different anti-
psychotic was started within at least 3 weeks, or if the
two antipsychotic prescriptions overlapped with a titration
down (eventually ending in termination) within 3 weeks.
Switches were classified into one of four categories, based
on previously defined approaches: [26,29,30] (i) titrated
switches where at least one drug was tapered, (ii) immedi-
ate switches where the first drug was terminated and the
second drug started abruptly with no overlap or tapering,
(iii)“gap” switches, with a gap of less than 3 weeks between
antipsychotic prescriptions, and (iv) “overlapped” switches
where both the initial and the new antipsychotic were
given concurrently for some period of less than three
weeks ending in a termination of the first antipsychotic
with no titration down. Psychiatric diagnoses represent
diagnoses made by physicians at the time of discharge
from the hospital. All psychiatric diagnoses were obtained
from electronic mental health records or physician’s notes
within the patient’s medical chart.
Results
In the year prior to hospital admission, there were
4818 weeks of antipsychotic prescription which were
given to a total of 139 patients. Following hospital ad-
mission there were 315.4 weeks of prescriptions recor-
ded. The mean age of patients was 12.9 ± 3.0 years, and
the population was 63% male. Primary psychiatric diag-
nosis at discharge was attention deficit hyperactivity dis-
order in 35 patients, anxiety in 35 patients, depressive
disorder in 19 patients, autism in 18 patients, psychosis
in 14 patients, bipolar disorder in 12 patients and tic/
neurological disorder in 2 patients (Table 1). Antipsy-
chotic drug dosing, based on chlorpromazine equiva-
lents, differed significantly between diagnoses [F(7,137) =
5.86, p < 0.0001)], with dosing notably lower in the two
largest treatment group of ADHD and anxiety patients
than for patients with depression, bipolar disorder or
psychosis. Antipsychotic polypharmacy (i.e., concurrent
administration of two or more antipsychotic drugs) was
noted in 35 patients during the study period. Psycho-
therapeutic drug combination therapy was relatively
common. Of the 139 patients receiving antipsychotic
treatment, 56 patients were concurrently treated at some
point with a psychostimulant/ADHD medication, 70 pa-
tients with an antidepressant, 33 patients with a mood
stabilizer, 11 with a benzodiazepine, and 39 with any
other class of psychotropic drug (such as a sleep medica-
tion). By comparison, only two patients were treated
with a diabetic medication, and 12 were prescribed an
antihypertensive agent.Risperidone was the most commonly prescribed anti-
psychotic at the time of discharge from the hospital
(34% of patients) followed by quetiapine (32% of patients),
and olanzapine (9%) (Table 2). The first generation drugs
chlorpromazine, haloperidol, loxapine, methotrimepra-
zine, perphenazine, pimozide, and the second generation
drug ziprasidone accounted for only 7 patients, indicating
infrequent use of first generation drugs and the low meta-
bolic risk second generation antipsychotic ziprasidone.
There were no prescriptions of clozapine prior to hospital
admission, and only one for aripiprazole following ad-
mission (aripiprazole was approved in Canada in 2009).
Drug dosing, based on chlorpromazine equivalent doses,
differed significantly between the antipsychotic drugs
[F(5,111) = 8.27, p < 0.0001)]. Amongst the three most com-
monly prescribed drugs, doses of risperidone were con-
spicuously lower than for olanzapine or quetiapine.
Changes to antipsychotic medication were relatively
common in the year before hospital admission, and this
frequency increased considerably following admission
(Table 3). Of the 139 patients who received antipsychotic
prescriptions in the year prior to admission, 25 patients
switched between antipsychotic medications at some
point during the year prior to their hospital admission, 1
of these patients switched antipsychotic medications
twice, and 6 different patients switched antipsychotics
following hospital admission for a total of 31 patients
switching antipsychotics 32 times. Also, 99 unique pa-
tients started an antipsychotic prescription a total of 144
times, and 63 patients terminated an antipsychotic pre-
scription a total of 90 times in the 12 months prior to
hospital admission. Following admission, a total of 15
patients started antipsychotics 23 times, and 11 patients
stopped antipsychotics 14 times. Many of the switches
recorded (40.6%, 13 of 32) were in patients changing
from risperidone to quetiapine. Switches from rispe-
ridone to olanzapine, quetiapine to risperidone, and
quetiapine to olanzapine each occurred in 4 (12.5%) pa-
tients. Of the other switches that were performed, halo-
peridol, aripiprazole, and chlorpromazine were involved
in only two switches, and loxapine was involved in a
single switch.
The average maintenance doses were also analyzed for
the drugs given before and after all switches. Equivalent
dosing of risperidone, olanzapine and quetiapine did not
differ significantly before or after the switch with the ex-
ception of a single patient who was receiving a mainten-
ance dose of 1000 mg quetiapine and switched to 10 mg
of olanzapine (Table 4). All doses before and after swit-
ches were also converted to chlorpromazine equivalent
doses, as previously [31,32]. Chlorpromazine equivalent
doses did not change significantly following the switch.
Many of the switches (11 of 32) were clearly titrated,
however switches with no sign of titration or a small gap
Table 1 Characterization of study population receiving treatment with an antipsychotic medication
Depressive disorder Anxiety Attention-deficit
hyperactivity disorder
Psychosis Bipolar disorder Substance abuse Autism Tics/Neurological
disorder
Subjects (M/F) 19 (6/13) 35 (27/8) 35 (26/9) 14 (8/6) 12 (6/6) 3 (2/1) 18 (12/6) 2 (2/0)
Mean Age (SD) 15.05 (1.92) 11.10 (2.81) 10.45 (2.60) 15.65 (1.25) 13.07 (3.22) 15.76 (0.54) 12.42 (3.17) 10.41 (2.21)
Risperidone (% of Dx group) 3 (15.8) 14 (40.0) 17 (48.6) 5 (35.7) 1 (8.3) 0 (0.0) 7 (38.9) 0 (0.0)
Mean Dose mg (SD) 0.92 (0.63) 0.89 (0.50) 1.01 (0.50) 2.20 (1.10) 1.00 0 1.54 (1.10) 0
Olanzapine (% of Dx group) 5 (26.3) 0 (0.0) 0 (0.0) 5 (35.7) 0 (0.0) 0 (0.0) 3 (16.7) 0 (0.0)
Mean Dose mg (SD) 6.00 (1.37) 0 0 15.00 (3.54) 0 0 11.67 (2.89) 0
Quetiapine (% of Dx group) 7 (36.8) 11 (31.4) 7 (20.0) 5 (35.7) 8 (66.7) 0 (0.0) 5 (27.8) 1 (50.0)
Mean Dose mg (SD) 251.79 (195.31) 138.64 (128.51) 89.29 (34.93) 325.00 (269.26) 276.56 (208.14) 0 160.00 (96.18) 75
Ziprasidone (% of Dx group) 0 (0.0) 0 (0.0) 1 (2.9) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mean Dose mg (SD) 0 0 40 20 0 0 0 0
Aripiprazole (% of Dx group) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mean Dose mg (SD) 0 0 0 7.5 0 0 0 0
FGAs (% of Dx group) 2 (10.5) 0 (0.0) 0 (0.0) 2 (14.3) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0)
Mean Dose mg (SD) - - - - - - - -
CPZ Equiv mg (SD) 220.60 (217.14) 110.76 (134.21) 73.44 (54.30) 316.07 (253.32) 333.33 (280.50) 0 186.01 (185.73) 100.00
# Emergency Visits (SD) 0.58 (0.77) 0.66 (1.37) 0.74 (1.77) 0.79 (1.19) 0.33 (0.78) 1.67 (1.15) 0.78 (2.07) 1.50 (2.12)
Switched Pre Hosp (% of Dx group) 7 (36.8) 5 (14.3) 6 (17.1) 1 (7.1) 3 (25.0) 1 (33.3) 2 (11.1) 1 (50.0)
Switched Post Hosp (% of Dx group) 0 (0.0) 0 (0.0) 1 (2.9) 4 (28.6) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0)
139 patients were identified who had been treated with an antipsychotic drug either during hospital admission or in the 52 weeks prior to admission. Table indicates characteristics of groups based on different

















Table 2 Characterization of study population receiving treatment with an antipsychotic medication
Risperidone Olanzapine Quetiapine Ziprasidone Aripiprazole FGAs No medication
Subjects (M/F) 47 (35/12) 13 (6/7) 44 (29/15) 2 (2/0) 1 (0/1) 5 (3/2) 39 (22/17)
Mean Age (SD) 11.54 (3.13) 15.16 (2.12) 13.31 (2.97) 14.63 (0.36) 16.77 15.22 (1.16) 11.88 (3.27)
Mean Dose mg (SD) 1.18 (0.78) 10.77 (4.83) 196.02 (175.58) 30.00 (14.14) 7.50 - -
CPZ Equiv mg (SD) 58.78 (39.09) 215.38 (96.58) 261.36 (234.10) 50.00 (23.57) 100.00 119.29 (111.33) -
On-Label Use (% of total on drug) 11 (23.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0 (0.0) -
Off-Label Use (% of total on drug) 36 (76.6) 13 (100.0) 44 (100.0) 2 (100.0) 0 (0.0) 5 (100.0) -
Titrated Switch Pre Hosp (% of switches) 1 (3.1) 2 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 2 (6.3)
Titrated Switch Post Hosp (% of switches) 1 (3.1) 2 (6.3) 2 (6.3) 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0)
Immediate Switch Pre Hosp (% of switches) 0 (0.0) 0 (0.0) 2 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.3)
Immediate Switch Post Hosp (% of switches) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gap Switch Pre Hosp (% of switches) 0 (0.0) 2 (6.3) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 3 (9.4)
Gap Switch Post Hosp (% of switches) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Overlapped Switch Pre Hosp (% of switches) 3 (9.4) 1 (3.1) 4 (12.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.3)
Overlapped Switch Post Hosp (% of switches) 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
139 patients were identified who had been treated with an antipsychotic drug either during hospital admission or in the 52 weeks prior to admission. Table indicates characteristics of groups based on different
































Before Admission 4321 26 0.313 144 1.733 90 1.083
After Admission 247.7 6 1.260 23 4.828 14 2.939
Starts were defined as any new antipsychotic prescription following a period of at least 3 weeks with no antipsychotic prescriptions; similarly stops were defined
as the discontinuation of antipsychotic prescription for at least three weeks. Switches were defined as a new antipsychotic medication started within three weeks
(before or after) the termination or beginning of titrating down to termination of another antipsychotic prescription. Frequencies were compared using a
Chi-squared test, and all changes were significant.
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32 respectively), and tended to occur with a higher fre-
quency closer to admission (Figure 1). There were also a
notable proportion of switches where the two drugs
were prescribed concurrently for a short period with no
tapering of either dose (10 of 32 switches).
Discussion
In the present study, we characterized a number of dif-
ferent variables related to antipsychotic drug switching
in youth, including frequency of switches, antipsychotic
drugs involved and method of switching prior and dur-
ing admission to a tertiary care psychiatric hospital. The
population was heterogeneous in terms of diagnoses,
with 63% of all patients having a diagnosis of an anxiety
disorder, autism or ADHD at the time of discharge. Dos-
ing in patients treated with risperidone at time of dis-
charge was significantly lower than in patients treated
with the alternate second generation antipsychotic drugs
olanzapine or quetiapine. This likely reflects the more
selective use of risperidone for disruptive behavior and/
or anxiety than the other antipsychotics which are pre-
ferred for treating the symptoms of psychosis or bipolar
disorder.
The frequency of switching in children and adoles-
cents in this cohort was similar to reported frequencies
in adults. The rate of 0.31 switches per year of therapy
in the community is very close to the rate of 29.5% that
was found by Nyhuis et al. [20] in a prospective adult
cohort (n = 648), although somewhat lower than the rate
of 42% reported by Covell et al. [24] in a chart review of
400 adults with schizophrenia. Whether this difference
with the latter study may be due to the age of the current
population or use of antipsychotics for disorders primarily
other than psychosis remains unknown. Following ad-
mission to the B.C. Children’s Hospital, modifications toTable 4 Average, minimum, and maximum maintenance dose
Prior to switch
Drug Average Minimum Maximum
Risperidone (n = 19) 1.24 0.25 2.5
Olanzapine (n = 3) 10 5 15
Quetiapine (n = 8) 168.75 25 1000
Both prior to switching, and following a switch between antipsychotic medications.
antipsychotic medication.antipsychotic therapy were made more frequently. This is
perhaps not unexpected, as any patient experiencing an
exacerbation of their symptoms may tend to be admitted
and switch antipsychotics due to a lack of efficacy. How-
ever, it is unclear whether the increased switch frequency
following admission may also result from differences in
prescribing practices between hospital and community
physicians, including general practitioners [6].
It is notable that a large proportion of the switches
(13, 40.6%) were made from risperidone to quetiapine. A
limitation of the current study is that we were not able
to ascertain the physician’s reasons for switching anti-
psychotic drugs. Thus, we do not know whether these
switches were related to a lack of efficacy or an intoler-
ance to drug side-effects. For example, risperidone has
been associated with equal if not greater efficacy in con-
trolling psychosis in youth [33]. While metabolic side-
effects are generally similar between the two drugs [34],
risperidone has been associated with higher rates of
extrapyramidal symptoms, akathisia and elevated prolac-
tin levels than quetiapine [35,36]. A large proportion of
switches from risperidone to quetiapine would therefore
be consistent with a lack of drug tolerance in patients,
but prospective studies are needed to confirm such hy-
potheses. The similar levels of dosing before and after
antipsychotic switches suggest that the new drug started
following a switch did not tend to be effective at lower
doses than the drug that was being discontinued. Con-
versely, the lack of a significant increase in dosing fol-
lowing the switch suggests a level of consistency in dose
in terms of chlorpromazine equivalent doses on the part
of physicians.
When analyzing the patterns of switching, it was clear
that no one particular type of drug switch strategy was
predominant. Titrated switches accounted for approxi-
mately one third of all switches, while “abrupt” switchess for antipsychotics
Following switch
Drug Average Minimum Maximum
Risperidone (n = 5) 1.2 0.5 4.0
Olanzapine (n = 9) 9.17 5 15
Quetiapine (n = 13) 95.8 37.5 150
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Overlap – no Titration 
Titrated
Figure 1 Distribution and type of switch between antipsychotics made in 52-weeks prior to hospital admission. Titrated switches were
defined as any switch involving either a gradual reduction in dose of the old antipsychotic or a gradual increase in the new antipsychotic within
3 weeks of starting the second drug. Immediate switches were made with no overlap between the two drugs, and no titration. Gap switches
involved the termination of one medication with a period of less than three weeks where there were no records of antipsychotic prescriptions
prior to starting a different antipsychotic. Overlapped switches involved the two drugs being prescribed concurrently for a period of less than
three week with no reduction of dose in the initial antipsychotic, nor a gradual increase in dose in the second drug.
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evident as concurrent administration of full doses of two
drugs for a period followed by abrupt termination of the
initial drug. We found no evidence for other types of
switches, including the “plateau cross-taper switch”
[29,30] (i.e. gradual start of new antipsychotic, followed
by treatment with full dose of both drugs, followed by
tapering of the original antipsychotic). However, given
the modest number of total switches out of a total of
4818 weeks of antipsychotic drug prescription, it is likely
that additional strategies for switching antipsychotic
drugs would have been evident with a larger sample size.
It has been suggested that specific switching strategies
may be best suited to certain antipsychotic drug combi-
nations. For example, Buckley and Correll suggested that
the plateau cross-titration switch may be preferable for a
switch to a drug with a long half-life, such as aripipra-
zole [29]. We did not find strong evidence for specific
patterns of drug switches with specific antipsychotic
drug combinations, but again this may reflect the need
to reproduce these findings in a considerably larger
dataset. However, we did note a greater proportion of ti-
trated switches following admission to hospital com-
pared to prior to admission. This may reflect the high
level of expertise and knowledge about antipsychoticdrug use and drug titration at the tertiary care facility
compared to community settings.
By examining the data on switching longitudinally in
the year prior to admission to the hospital, we were able
to determine that the frequency of all switches–parti-
cularly those without any kind of titration–was clearly
higher approaching hospital admission. This finding is
open to interpretation. It seems most likely that this re-
flects a worsening of symptoms which remain refractory
to drug treatment, ultimately leading to hospitalization,
with switches occurring as an attempt to improve clini-
cal efficacy. While inopportune antipsychotic drug swit-
ching can cause adverse effects [25], it would be unlikely
for these effects to result in hospitalization.
Conclusions
In summary, to our knowledge the present findings
describe for the first time the frequencies of different
patterns of antipsychotic drug switching techniques used
in youth with a heterogeneous diagnostic background.
Three distinct patterns of switches occurred with similar
frequency. Less common switching patterns may also be
present in the larger population, as well as switches as-
sociated with specific antipsychotic drug combinations.
However, observation of these may require the use of
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Nevertheless, the present study has indicated the feasi-
bility of studying such switches retrospectively using
non-chart based procedures, which may be useful for
understanding how switching occurs at a larger scale. Ef-
fective antipsychotic drug switching remains an import-
ant concern, and suboptimal switching may contribute
to both patient discomfort and lack of drug adherence.
A better understanding of how most antipsychotic drugs
switches happen may be one of the first steps to ad-
dressing this amenable issue.
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